Raptiva
Raptiva Linked to Neurologic Disorder
According to the FDA, on April 8, 2009, Raptiva - a psoriasis drug - was voluntarily withdrawn from the US market by its manufacturer, Genentech. The action was taken as a result of a potential link to the development of progressive multifocal leukoencephalopathy (PML). PML is a serious and progressive neurologic disorder caused by a virus (polyomavirus or JC virus) that affects the central nervous system. Raptiva is a administered by an injection once a week. It has been on the market since 2003. Raptiva is also known as Efalizumab.
Patients at Risk
The risk for contacting PML is generally associated with long term use of Raptiva. Individuals with weakened immune systems are at greater risk. PML may lead to an irreversible decline in neurologic function and eventually death. Currently, there is no treatment for PML.
Action
Genentech has stated that it is not possible to identify patients at increased risk of PML. The manufacturer recommends that patients contact their physicians and transition to another medication.
If you or a loved one has suffered PML, bacterial sepsis, invasive fungal disease or other neurologic impairments such as visual impairment, speech problems, clumsiness, dizziness or personality changes, you may have a claim for damages.
Contact Raptiva lawyer Mike Sudekum by calling the toll free number or using the contact us page of this website for a free discussion of your legal rights.
According to the FDA, on April 8, 2009, Raptiva - a psoriasis drug - was voluntarily withdrawn from the US market by its manufacturer, Genentech. The action was taken as a result of a potential link to the development of progressive multifocal leukoencephalopathy (PML). PML is a serious and progressive neurologic disorder caused by a virus (polyomavirus or JC virus) that affects the central nervous system. Raptiva is a administered by an injection once a week. It has been on the market since 2003. Raptiva is also known as Efalizumab.
Patients at Risk
The risk for contacting PML is generally associated with long term use of Raptiva. Individuals with weakened immune systems are at greater risk. PML may lead to an irreversible decline in neurologic function and eventually death. Currently, there is no treatment for PML.
Action
Genentech has stated that it is not possible to identify patients at increased risk of PML. The manufacturer recommends that patients contact their physicians and transition to another medication.
If you or a loved one has suffered PML, bacterial sepsis, invasive fungal disease or other neurologic impairments such as visual impairment, speech problems, clumsiness, dizziness or personality changes, you may have a claim for damages.
Contact Raptiva lawyer Mike Sudekum by calling the toll free number or using the contact us page of this website for a free discussion of your legal rights.